Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEUS in Post-Surgical Pancreatic Cancer Patients
NCT07910383Recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial of sulfur hexafluoride in pancreatic ductal adenocarcinoma (PDAC), sponsored by Thomas Jefferson University. Primary endpoint: Presence of Contrast Enhancement in the Pancreatic Surgical Site on CEUS at 1 hour. Started Jul 2026; status: recruiting.
02
Drugs
sulfur hexafluoride
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07910383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07910383.